Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 426 to 450 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
426 increased gene expression (GO:0010467) hypoxia-inducible factor 1-alpha (PR:000008555)
427 abnormal signaling (GO:0023052) hypoxia-inducible factor 1-alpha (PR:000008555) 801: modulation, Unknown
428 decreased mevalonate (CHEBI:25350) 805: Decreased, mevalonate
429 decreased cholesterol (CHEBI:16113) None
430 decreased hydroxymethylglutaryl-CoA reductase activity (GO:0042282) 3-hydroxy-3-methylglutaryl-coenzyme A reductase (PR:000008636) 804: Inhibition, HMG-CoA reductase
431 morphological change male reproductive system (UBERON:0000079) 809: malformed, Male reproductive tract
432 decreased reduced fertility (MP:0001921) fertility (MESH:D005298) 527: Decreased, Decreased fecundity
433 decreased hormone secretion (GO:0046879) Luteinizing hormone (CHEBI:81568)
434 decreased norepinephrine binding (GO:0051380) (R)-noradrenaline (CHEBI:18357) 848: Decreased, Binding of NE to NE receptors on GnRH neurons
435 decreased signaling (GO:0023052) alpha-2A adrenergic receptor (PR:000001186) 849: Inhibition, Antgonism of NE receptor
436 decreased glomerular filtration (GO:0003094) 819: Decreased, Glomerular filtration
437 decreased kidney plasma flow trait (VT:0005524) 820: Decreased, Renal plasma flow
438 decreased renal absorption (GO:0070293) sodium(1+) (CHEBI:29101) 821: Decreased, Sodium reabsorption
439 decreased function (MI:0613) kidney (UBERON:0002113) 825: Decreased, Renal ability to dilute urine
440 increased creatinine (CHEBI:16737) 813: Increased, Serum creatinine
441 increased abnormal amino acid level (MP:0005332) 813: Increased, Serum creatinine
442 occurrence toxicity (MESH:Q000633) kidney (UBERON:0002113) 814: Occurrence, Kidney toxicity
443 occurrence autophagic cell death (GO:0048102) renal tubule (UBERON:0009773) 818: Occurrence, Cytoplasmic vacuolization (Renal tubule)
444 occurrence Dilatation (MESH:D004106) renal tubule (UBERON:0009773) 823: Occurrence, Cystic dilatation (renal tubule)
445 occurrence podocyte vacuolization (MP:0011899) 824: Occurrence, Cytoplasmic vacuolization (podocyte)
446 functional change Lipid bilayer of wall of lysosome (FMA:67514) 829: Damage, Lipid bilayer
447 occurrence Mallory bodies (MP:0014045) 839: Formation, Mallory body
448 increased Microvesicular hepatic steatosis (HP:0001414) 838: Induction, Microvesicular fat
449 decreased phospholipase activity (GO:0004620) phospholipase A1 member A (human) (PR:Q53H76) 828: Inhibition, Phospholipase A
450 occurrence autophagic cell death (GO:0048102)